The new BSR Psoriatic Arthritis Guidelines with Dr William Tillett

<p>This episode shares information about the new British Society for Rheumatology treatment guidelines for Psoriatic Arthritis . Mel Brooke, the Patient and Public Engagement Programme Director (BIRD) talks with expert guest Dr William Tillett, Consultant Rheumatologist, RNHRD, RUH Bath who explains what the guidelines are and how they have been updated.</p> <p>If you can please rate our podcasts on your listening platform.  Did you know you can also access all our information podcasts direct from BIRDs website?  Simply visit <a href="https://www.birdbath.org.uk/podcasts">⁠www.birdbath.org.uk/podcasts⁠</a> and scroll down the page to find the one you are looking for.</p> <p>Useful links:</p> <p><a href="https://www.informatree.org" target="_blank" rel="noopener noreferer">The Informatree for PsA</a></p> <p><a href="https://www.papaa.org" target="_blank" rel="noopener noreferer">PAPAA</a></p> <p><a href="https://www.psoriasis-association.org.uk/">⁠Psoriasis Association⁠</a></p> <p><a href="https://www.versusarthritis.org" target="_blank" rel="noopener noreferer">Versus Arthritis </a></p> <p><a href="https://www.grappanetwork.org" target="_blank" rel="noopener noreferer">GRAPPA</a></p> <p>Please note: All content for BIRD&#39;s PPE podcasts are created for information purposes only and not intended to be a substitute for individual medical advice, diagnosis, or treatment. Always seek the advice of your physician or health provider with any questions you may have about your medical condition. Reliance on any information provided by BIRD or any of the expert podcast guests is solely at your own risk.</p> <p>The Patient and Public Engagement Programme is supported by hands-off sponsorships from Eli Lilly and Company Limited, UCB and Amgen - all of whom have provided grant funding but who have had no involvement in the development, content or editorial control of this podcast, nor the subsequent review and approval of these materials or general running of the patient and public engagement programme.</p> <p>We would als